Jump to ContentJump to Main Navigation

Clinical Chemistry and Laboratory Medicine (CCLM)

Published in Association with the European Federation of Clinical Chemistry and Laboratory Medicine (EFLM)

Editor-in-Chief: Plebani, Mario

Ed. by Gillery, Philippe / Lackner, Karl J. / Lippi, Giuseppe / Melichar, Bohuslav / Schlattmann, Peter / Tate, Jillian R. / Tsongalis, Gregory J.

12 Issues per year


IMPACT FACTOR 2014: 2.707
Rank 6 out of 30 in category Medical Laboratory Technology in the 2014 Thomson Reuters Journal Citation Report/Science Edition

SCImago Journal Rank (SJR): 0.860
Source Normalized Impact per Paper (SNIP): 1.046

VolumeIssuePage

Issues

Increased Serum Neopterin Concentrations in Patients with Alzheimer’s Disease

Friedrich Leblhuber / Johannes Walli / Ulrike Demel / Gernot P. Tilz / Bernhard Widner / Dietmar Fuchs

Citation Information: Clinical Chemistry and Laboratory Medicine. Volume 37, Issue 4, Pages 429–431, ISSN (Print) 1434-6621, DOI: 10.1515/CCLM.1999.070, June 2005

Publication History

Published Online:
2005-06-01

Abstract

We measured serum neopterin concentrations in 24 patients with Alzheimer's disease (8 males, 16 females; age: 73.1 ± 6.2 years; free of any infectious process) and fourteen controls of similar age (4 males, 10 females; age: 69.7 ± 8.8 years). Compared to controls, significantly higher concentrations of neopterin (p < 0.01) were found in patients with Alzheimer's disease. Among patients, concentrations of neopterin were higher in those with lower mini-mental-state (p < 0.05), and an invers correlation existed between mini-mental-state and neopterin concentrations. No such association existed with the duration of the disease. There were also significant correlations between neopterin and serum concentrations of immune activation markers such as soluble tumor necrosis factor (TNF) receptor and soluble interleukin-2 receptor (all p < 0.01). Thus, increased concentrations of neopterin in serum of patients with Alzheimer's disease correlate with the severity of dementia. The data imply a chronic state of peripheral immune activation in Alzheimer's disease.

Citing Articles

Here you can find all Crossref-listed publications in which this article is cited. If you would like to receive automatic email messages as soon as this article is cited in other publications, simply activate the “Citation Alert” on the top of this page.

[1]
Philipp Wissmann, Simon Geisler, Friedrich Leblhuber, and Dietmar Fuchs
Journal of the Neurological Sciences, 2013, Volume 329, Number 1-2, Page 29
[2]
Barbara Sperner-Unterweger, Claudia Kohl, and Dietmar Fuchs
Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2014, Volume 48, Page 268
[3]
Peter Svoboda, Seong-Hee Ko, BeLong Cho, Sang-Ho Yoo, Seong-Won Choi, Sang-Kyu Ye, Hiroshi Kasai, and Myung-Hee Chung
Analytical Biochemistry, 2008, Volume 383, Number 2, Page 236
[4]
Christiane Enzinger, Barbara Wirleitner, Günther Böck, Gabriele Baier-Bitterlich, and Dietmar Fuchs
Neuroscience Letters, 2001, Volume 316, Number 3, Page 157
[5]
J.Antonio Casal, Alfredo Robles, and J.Carlos Tutor
Clinical Biochemistry, 2003, Volume 36, Number 7, Page 553
[6]
Christian Murr, Katharina Schroecksnadel, Diether Schönitzer, Dietmar Fuchs, and Harald Schennach
Clinical Biochemistry, 2005, Volume 38, Number 10, Page 916
[7]
Kang Soo Lee, Ji Hyung Chung, Kyung Hye Lee, Min-Jeong Shin, Byoung Hoon Oh, and Chang Hyung Hong
Immunology Letters, 2008, Volume 121, Number 2, Page 105
[8]
Pankaj D. Mehta, George Capone, Amy Jewell, and Robert L. Freedland
Journal of the Neurological Sciences, 2007, Volume 254, Number 1-2, Page 22
[10]
Federico Licastro, Steve Pedrini, Ludovica Caputo, Giorgio Annoni, Lizabeth Jane Davis, Cinzia Ferri, Valeria Casadei, and Luigi Maria Edoardo Grimaldi
Journal of Neuroimmunology, 2000, Volume 103, Number 1, Page 97
[11]
Gozde Girgin, Terken Baydar, Maximilian Ledochowski, Harald Schennach, Duygu Nur Bolukbasi, Kadriye Sorkun, Bekir Salih, Gonul Sahin, and Dietmar Fuchs
Immunobiology, 2009, Volume 214, Number 2, Page 129
[12]
Imrich Blasko, Gabriele Knaus, Elisabeth Weiss, Georg Kemmler, Christiana Winkler, Gerda Falkensammer, Andrea Griesmacher, Reinhard Würzner, Josef Marksteiner, and Dietmar Fuchs
Journal of Psychiatric Research, 2007, Volume 41, Number 8, Page 694
[13]
Friedrich Leblhuber, Katharina Schroecksnadel, Margit Beran-Praher, Herbert Haller, Kostja Steiner, and Dietmar Fuchs
Journal of Neural Transmission, 2011, Volume 118, Number 5, Page 721
[14]
Dietmar Fuchs, Matthias Jaeger, Bernhard Widner, Barbara Wirleitner, Erika Artner-Dworzak, and Friedrich Leblhuber
Clinical Chemistry and Laboratory Medicine, 2001, Volume 39, Number 8
[15]
Kavon Rezai-Zadeh, David Gate, Christine  A Szekely, and Terrence Town
Expert Review of Neurotherapeutics, 2009, Volume 9, Number 11, Page 1623
[16]
M. E. Spencer, A. Jain, A. Matteini, B. A. Beamer, N.-Y. Wang, S. X. Leng, N. M. Punjabi, J. D. Walston, and N. S. Fedarko
The Journals of Gerontology Series A: Biological Sciences and Medical Sciences, 2010, Volume 65A, Number 8, Page 858
[17]
Katharina Schroecksnadel, Friedrich Leblhuber, Barbara Frick, Barbara Wirleitner, and Dietmar Fuchs
Alzheimer Disease & Associated Disorders, 2004, Volume 18, Number 3, Page 129
[18]
Craig J. Wilson, Caleb E. Finch, and Harvey J. Cohen
Journal of the American Geriatrics Society, 2002, Volume 50, Number 12, Page 2041
[19]
Jos� I. Lao, Katrin Beyer, and Aurelio Ariza
Drug Development Research, 2004, Volume 62, Number 3, Page 221

Comments (0)

Please log in or register to comment.